Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.
- First Remplir surgical case completed in US DoD/VA hospital network
- Approval grants access to 221 military and veteran hospitals nationwide
- Rapid surgeon engagement supports Orthocell’s US commercial strategy
- US distributors active across 17 states to drive further uptake
- Builds on broader US rollout and growing surgeon adoption
First Surgery Signals Rapid Uptake in US Military Hospitals
Orthocell Limited (ASX:OCC) has transformed recent regulatory approval into immediate clinical application, completing the first Remplir™ surgical case within the US Department of Defense (DoD) and Veterans Affairs (VA) hospital network. The procedure, conducted at a military hospital in Ohio, underscores the company’s ability to swiftly translate approvals into real-world use, a critical milestone for its US commercialisation ambitions.
This initial surgery follows Orthocell’s announcement on 15 April 2026 confirming Remplir’s clearance for supply across 221 hospitals comprising 51 DoD military hospitals and 170 VA medical centres. The rapid deployment highlights strong surgeon engagement within these systems and validates the effectiveness of Orthocell’s established US distributor network, which already spans 17 states and facilitates efficient onboarding and case support.
Distributor Network and Surgeon Engagement Drive Growth
Orthocell’s US commercial footprint is gaining momentum, with distributors playing a pivotal role in supporting further adoption of Remplir across military and veteran healthcare systems. This progress is part of a wider US rollout strategy that has seen growing hospital access and surgeon participation, building on the company’s expanding presence in the country.
Orthocell’s Managing Director Paul Anderson emphasised the significance of this milestone, noting the clinical relevance of Remplir for complex nerve injuries and the company’s capacity for rapid execution once access is secured. He highlighted that military and veteran healthcare systems often manage some of the most challenging trauma cases, making early surgical uptake an encouraging indicator for continued expansion.
Broader US Commercialisation Momentum
This development complements Orthocell’s broader US commercialisation progress, including recent achievements such as the approval for Remplir in the US Defence network. The company has recorded initial sales and continues to build surgeon engagement, positioning itself to capture a growing share of the regenerative medicine market focused on nerve repair.
Orthocell’s portfolio, which includes collagen medical devices and autologous cell therapies, is increasingly gaining traction across multiple jurisdictions. The company’s strategy to leverage distribution partnerships and clinical validation is central to scaling revenues in both military and civilian hospital systems throughout the US.
Bottom Line?
Orthocell’s swift surgical adoption in US military hospitals marks a tangible step in commercialising Remplir, but sustained growth will hinge on ongoing surgeon engagement and distributor effectiveness.
Questions in the middle?
- How quickly will Remplir adoption scale across the full 221 DoD and VA hospitals?
- What impact will military and veteran trauma case complexity have on Remplir’s clinical demand?
- Can Orthocell’s distributor network maintain momentum amid broader US hospital rollouts?